Sernova Biotherapeutics Inc
Sernova Biotherapeutics Inc is a clinical-stage Canadian biotechnology company specializing in regenerative medicine therapeutics. The company focuses on developing its proprietary Cell Pouch System, an implantable and scalable medical device designed to create a vascularized, organ-like environment for the transplantation and engraftment of therapeutic cells. This technology aims to restore natural physiological functions by enabling transplanted cells within the Cell Pouch to generate proteins, hormones, or factors released into the bloodstream, targeting chronic diseases such as insulin-dependent diabetes, thyroid disorders, and blood conditions like hemophilia A. Founded in 1998 and headquartered in London, Canada, Sernova represents innovative advances in biopharmaceutical development, marrying cell therapy with bioengineering to provide potential functional cures and improve patients' quality of life through durable, retrievable implants.
$6.47
+$0.00 (+0.00%)
Price from 94 days ago
ROIC dropped from -378.41% to -444.20%, capital efficiency is deteriorating. Negative free cash flow of -C$11M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
C$0.00
Net Income (TTM)
-C$12M
▲ +51.1% YoY
Op. Margin
—
ROIC
-444.20%
▼ -65.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-C$5M
▲ +42.3% YoY
Op. Cash Flow (TTM)
-C$5M
▲ +42.3% YoY
Net Debt
C$5M
Cash & Equiv.
C$265K
Continue Research
Is Sernova Biotherapeutics (SVA) overvalued?
Sernova Biotherapeutics (SVA)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Sernova Biotherapeutics scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Sernova Biotherapeutics a high-quality business?+
Sernova Biotherapeutics scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -444.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Sernova Biotherapeutics a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh SVA's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.